Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Show Submenu For Accessing medicines
Access to medicines in Wales
Medicine recommendations
Make a submission
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Who we are
What we do
Our committees
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
TA918: Bimekizumab for treating axial spondyloarthritis
TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA718: Ixekizumab for treating axial spondyloarthritis
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
13/08/2020
TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
13/08/2020
TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
13/08/2020
TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
13/08/2020
TA432: Everolimus for advanced renal cell carcinoma after previous treatment (replaced TA219)
13/08/2020
TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
13/08/2020
TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (replaced TA222)
13/08/2020
TA230: Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
13/08/2020
TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (replaced TA205)
13/08/2020
TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
13/08/2020
TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
13/08/2020
TA461: Roflumilast for treating chronic obstructive pulmonary disease (replaced TA244)
13/08/2020
TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
13/08/2020
TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
13/08/2020
TA274: Ranibizumab for treating diabetic macular oedema (replaced TA237)
13/08/2020
TA236: Ticagrelor for the treatment of acute coronary syndromes
13/08/2020
TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
13/08/2020
TA149: Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)
13/08/2020
TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
12/08/2020
TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
12/08/2020
TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
1
2
3
4
5
6
7
8
9
10
11
Follow AWTTC:
